RU2734432C1 - Моноклональное антитело, которое специфически связывается с GITR - Google Patents

Моноклональное антитело, которое специфически связывается с GITR Download PDF

Info

Publication number
RU2734432C1
RU2734432C1 RU2019112296A RU2019112296A RU2734432C1 RU 2734432 C1 RU2734432 C1 RU 2734432C1 RU 2019112296 A RU2019112296 A RU 2019112296A RU 2019112296 A RU2019112296 A RU 2019112296A RU 2734432 C1 RU2734432 C1 RU 2734432C1
Authority
RU
Russia
Prior art keywords
amino acid
seq
antibody
acid sequence
monoclonal antibody
Prior art date
Application number
RU2019112296A
Other languages
English (en)
Russian (ru)
Inventor
Андрей Борисович Улитин
Олеся Николаевна Козлова
Александр Андреевич Гордеев
Ксения Михайловна Бурнышева
Анастасия Николаевна Ишутинова
Александра Александровна Созонова
Сергей Андреевич Агеев
Александр Николаевич Доронин
Владимир Сергеевич Цымпилов
Иван Владимирович Митрошин
Валерий Владимирович Соловьев
Яков Юрьевич Устюгов
Роман Алексеевич Иванов
Дмитрий Валентинович Морозов
Original Assignee
Закрытое Акционерное Общество "Биокад"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Закрытое Акционерное Общество "Биокад" filed Critical Закрытое Акционерное Общество "Биокад"
Priority to RU2019112296A priority Critical patent/RU2734432C1/ru
Priority to TW108144110A priority patent/TWI803718B/zh
Priority to CN201911222245.8A priority patent/CN110903392B/zh
Priority to UY0001038672A priority patent/UY38672A/es
Priority to KR1020217038209A priority patent/KR20220010501A/ko
Priority to MYPI2021006363A priority patent/MY210018A/en
Priority to PCT/RU2020/050080 priority patent/WO2020218951A2/ru
Priority to US17/605,933 priority patent/US12410257B2/en
Priority to MA54969A priority patent/MA54969B2/fr
Priority to BR112021021281A priority patent/BR112021021281A2/pt
Priority to EP20794288.9A priority patent/EP3964525A4/en
Priority to ARP200101146A priority patent/AR118763A1/es
Priority to EA202192907A priority patent/EA202192907A1/ru
Priority to JP2021563239A priority patent/JP7695200B2/ja
Priority to MX2021012962A priority patent/MX2021012962A/es
Priority to PE2021001765A priority patent/PE20220144A1/es
Priority to AU2020261207A priority patent/AU2020261207A1/en
Priority to CA3137822A priority patent/CA3137822A1/en
Priority to PY202002018606A priority patent/PY2018606A/es
Priority to MA55390A priority patent/MA55390B1/fr
Application granted granted Critical
Publication of RU2734432C1 publication Critical patent/RU2734432C1/ru
Priority to CONC2021/0014153A priority patent/CO2021014153A2/es
Priority to CL2021002792A priority patent/CL2021002792A1/es
Priority to IL287531A priority patent/IL287531A/en
Priority to JOP/2021/0286A priority patent/JOP20210286A1/ar
Priority to ZA2021/09374A priority patent/ZA202109374B/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2019112296A 2019-04-23 2019-04-23 Моноклональное антитело, которое специфически связывается с GITR RU2734432C1 (ru)

Priority Applications (25)

Application Number Priority Date Filing Date Title
RU2019112296A RU2734432C1 (ru) 2019-04-23 2019-04-23 Моноклональное антитело, которое специфически связывается с GITR
TW108144110A TWI803718B (zh) 2019-04-23 2019-12-03 與gitr特異性結合的單株抗體
CN201911222245.8A CN110903392B (zh) 2019-04-23 2019-12-03 与gitr特异性结合的单克隆抗体
UY0001038672A UY38672A (es) 2019-04-23 2020-04-22 Anticuerpo monoclonal que se une específicamente a gitr
PE2021001765A PE20220144A1 (es) 2019-04-23 2020-04-23 Anticuerpo monoclonal que se une especificamente a gitr
PCT/RU2020/050080 WO2020218951A2 (ru) 2019-04-23 2020-04-23 Моноклональное антитело, которое специфически связывается с gitr
US17/605,933 US12410257B2 (en) 2019-04-23 2020-04-23 Monoclonal antibody that binds specifically to GITR
MA54969A MA54969B2 (fr) 2019-04-23 2020-04-23 Anticorps monoclonal se liant spécifiquement à gitr
BR112021021281A BR112021021281A2 (pt) 2019-04-23 2020-04-23 Anticorpo monoclonal que se liga especificamente ao gitr
EP20794288.9A EP3964525A4 (en) 2019-04-23 2020-04-23 MONOCLONAL ANTIBODY SPECIFIC TO GITR BINDING
ARP200101146A AR118763A1 (es) 2019-04-23 2020-04-23 Anticuerpo monoclonal que se une específicamente a gitr
EA202192907A EA202192907A1 (ru) 2019-04-23 2020-04-23 Моноклональное антитело, которое специфически связывается с gitr
KR1020217038209A KR20220010501A (ko) 2019-04-23 2020-04-23 Gitr에 특이적으로 결합하는 단일클론 항체
MX2021012962A MX2021012962A (es) 2019-04-23 2020-04-23 Anticuerpo monoclonal que se une especificamente a gitr.
MYPI2021006363A MY210018A (en) 2019-04-23 2020-04-23 Monoclonal antibody that binds specifically to gitr
AU2020261207A AU2020261207A1 (en) 2019-04-23 2020-04-23 Monoclonal antibody that specifically binds to GITR
CA3137822A CA3137822A1 (en) 2019-04-23 2020-04-23 Monoclonal antibody that binds specifically to gitr
JP2021563239A JP7695200B2 (ja) 2019-04-23 2020-04-23 Ｇｉｔｒに特異的に結合するモノクローナル抗体
PY202002018606A PY2018606A (es) 2019-04-23 2020-05-06 Anticuerpo monoclonal que se une específicamente a GITR
MA55390A MA55390B1 (fr) 2019-04-23 2020-06-30 Dispositif pour découper l'adn à base de la protéine cas9 à partir de la bactérie pasteurella pneumotropica
CONC2021/0014153A CO2021014153A2 (es) 2019-04-23 2021-10-22 Anticuerpo monoclonal que se une específicamente a gitr
CL2021002792A CL2021002792A1 (es) 2019-04-23 2021-10-22 Anticuerpo monoclonal que se une específicamente a gitr
IL287531A IL287531A (en) 2019-04-23 2021-10-24 Monoclonal antibody that binds specifically to gitr
JOP/2021/0286A JOP20210286A1 (ar) 2019-04-23 2021-10-24 جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr
ZA2021/09374A ZA202109374B (en) 2019-04-23 2021-11-22 Monoclonal antibody that binds specifically to gitr

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2019112296A RU2734432C1 (ru) 2019-04-23 2019-04-23 Моноклональное антитело, которое специфически связывается с GITR

Publications (1)

Publication Number Publication Date
RU2734432C1 true RU2734432C1 (ru) 2020-10-16

Family

ID=69821666

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019112296A RU2734432C1 (ru) 2019-04-23 2019-04-23 Моноклональное антитело, которое специфически связывается с GITR

Country Status (24)

Country Link
US (1) US12410257B2 (https=)
EP (1) EP3964525A4 (https=)
JP (1) JP7695200B2 (https=)
KR (1) KR20220010501A (https=)
CN (1) CN110903392B (https=)
AR (1) AR118763A1 (https=)
AU (1) AU2020261207A1 (https=)
BR (1) BR112021021281A2 (https=)
CA (1) CA3137822A1 (https=)
CL (1) CL2021002792A1 (https=)
CO (1) CO2021014153A2 (https=)
EA (1) EA202192907A1 (https=)
IL (1) IL287531A (https=)
JO (1) JOP20210286A1 (https=)
MA (2) MA54969B2 (https=)
MX (1) MX2021012962A (https=)
MY (1) MY210018A (https=)
PE (1) PE20220144A1 (https=)
PY (1) PY2018606A (https=)
RU (1) RU2734432C1 (https=)
TW (1) TWI803718B (https=)
UY (1) UY38672A (https=)
WO (1) WO2020218951A2 (https=)
ZA (1) ZA202109374B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2724470C1 (ru) * 2019-11-11 2020-06-23 Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий Применение cas9 белка из бактерии pasteurella pneumotropica для модификации геномной днк в клетках
CN111732658B (zh) * 2020-06-28 2022-04-26 英诺湖医药(杭州)有限公司 一组gitr单克隆抗体及其医药用途
CN112540179B (zh) * 2020-08-06 2023-07-07 武汉天德生物科技有限公司 一种测试ApoE4蛋白含量的ELISA试剂盒
CN112362876B (zh) * 2020-08-06 2023-12-15 武汉天德生物科技有限公司 一种检测早期老年痴呆症的胶体金试纸条及其制备方法
CN111763257B (zh) * 2020-09-01 2020-12-15 北京百奥赛图基因生物技术有限公司 抗gitr抗体及其用途
CN114891111A (zh) * 2020-12-31 2022-08-12 中元汇吉生物技术股份有限公司 特异性结合人IgG4的蛋白及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2369636C2 (ru) * 2003-05-23 2009-10-10 Уайт Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения
RU2595409C2 (ru) * 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2006105062A2 (en) 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
CA2614181A1 (en) 2005-07-01 2007-01-11 Medimmune, Inc. An integrated approach for generating multidomain protein therapeutics
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
SG10201912986PA (en) * 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
EP3244926B8 (en) * 2015-01-14 2024-08-21 The Brigham and Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
EP3365371B1 (en) 2015-10-22 2025-10-08 Ablynx NV Gitr agonists
EP3383431A4 (en) 2015-12-02 2019-08-28 Agenus Inc. ANTI-GITR ANTIBODIES AND METHOD OF USE THEREOF
US10738126B2 (en) 2016-06-10 2020-08-11 Regeneron Pharmaceuticals, Inc. Anti-GITR antibodies and uses thereof
CN109641967A (zh) 2016-07-01 2019-04-16 戊瑞治疗有限公司 用GITR激动剂和CpG的组合的抗肿瘤疗法
CN109843916B (zh) 2016-08-12 2023-10-31 詹森生物科技公司 具有增强的激动活性的Fc工程化抗TNFR超家族成员抗体及其使用方法
CA3042727A1 (en) * 2016-11-19 2018-05-24 Potenza Therapeutics, Inc. Anti-gitr antigen-binding proteins and methods of use thereof
JP7231549B2 (ja) 2017-02-06 2023-03-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法
RU2019127550A (ru) * 2017-03-03 2021-04-05 Ринат Ньюросайенс Корп. Анти-gitr антитела и способы их использования
TWI788340B (zh) * 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2369636C2 (ru) * 2003-05-23 2009-10-10 Уайт Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения
RU2595409C2 (ru) * 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела
RU2646139C1 (ru) * 2009-09-03 2018-03-01 Мерк Шарп И Доум Корп. Анти-gitr-антитела

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIEDERBICK KD, SCHMIDT-WOLF IGH "Efficacy of cytokine induced killer cells targeting CD40 and GITR", ONCOLOGY LETTERS, 2019, Vol. 17, pp. 2425-2430, [дата обращения 23.07.2019], Найдено в Интернет: URL: https://www.spandidos-publications.com/ol/17/2/2425?text=fulltext. *
КАДАГИДЗЕ З.Г. "Новые подходы к регуляции противоопухолевого иммунитета", Маммология, 2007, No. 1, стр. 10-12. *
КАДАГИДЗЕ З.Г. "Новые подходы к регуляции противоопухолевого иммунитета", Маммология, 2007, No. 1, стр. 10-12. BIEDERBICK KD, SCHMIDT-WOLF IGH "Efficacy of cytokine induced killer cells targeting CD40 and GITR", ONCOLOGY LETTERS, 2019, Vol. 17, pp. 2425-2430, [дата обращения 23.07.2019], Найдено в Интернет: URL: https://www.spandidos-publications.com/ol/17/2/2425?text=fulltext. *

Also Published As

Publication number Publication date
CN110903392B (zh) 2024-02-13
MA55390A1 (fr) 2022-05-31
PE20220144A1 (es) 2022-01-27
JP7695200B2 (ja) 2025-06-18
CL2021002792A1 (es) 2022-06-24
TW202100554A (zh) 2021-01-01
WO2020218951A2 (ru) 2020-10-29
MY210018A (en) 2025-08-21
US20220213209A1 (en) 2022-07-07
TWI803718B (zh) 2023-06-01
ZA202109374B (en) 2022-12-21
EP3964525A4 (en) 2022-12-28
AR118763A1 (es) 2021-10-27
MA55390B1 (fr) 2022-10-31
IL287531A (en) 2021-12-01
JOP20210286A1 (ar) 2021-10-24
MA54969A1 (fr) 2022-08-31
MX2021012962A (es) 2021-12-15
CA3137822A1 (en) 2020-10-29
JP2022532991A (ja) 2022-07-21
PY2018606A (es) 2023-09-15
UY38672A (es) 2020-10-30
AU2020261207A1 (en) 2021-12-23
BR112021021281A2 (pt) 2022-03-08
KR20220010501A (ko) 2022-01-25
WO2020218951A3 (ru) 2020-12-24
EP3964525A2 (en) 2022-03-09
CN110903392A (zh) 2020-03-24
MA54969B2 (fr) 2025-10-31
EA202192907A1 (ru) 2022-01-25
CO2021014153A2 (es) 2021-10-29
US12410257B2 (en) 2025-09-09

Similar Documents

Publication Publication Date Title
JP7676474B2 (ja) Ｃｄ４７およびｐｄ－ｌ１に特異的な抗体
RU2734432C1 (ru) Моноклональное антитело, которое специфически связывается с GITR
AU2018255132B2 (en) Monoclonal antibody to PD-L1
IL282742B1 (en) Monoclonal antibody that binds uniquely to CD20
RU2779652C2 (ru) АНТИТЕЛА, СПЕЦИФИЧНЫЕ К CD47 и PD-L1
TW202003038A (zh) 特異性結合人ｈｅｒ２的細胞外結構域的亞結構域ｉｖ和ｉｉ的雙特異性抗體
EA044786B1 (ru) Моноклональное антитело, которое специфически связывается с gitr
HK40061004B (zh) 与cd20特异性结合的单克隆抗体
EA044757B1 (ru) Моноклональное антитело, которое специфически связывается с cd20
HK40061004A (en) Monoclonal antibody that specifically binds to cd20
EA041915B1 (ru) Моноклональное антитело к pd-l1